AM Investment Strategies LLC lessened its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 18,766 shares of the company’s stock after selling 274 shares during the period. Johnson & Johnson comprises about 1.2% of AM Investment Strategies LLC’s portfolio, making the stock its 21st biggest position. AM Investment Strategies LLC’s holdings in Johnson & Johnson were worth $3,315,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in JNJ. Veracity Capital LLC raised its position in shares of Johnson & Johnson by 1.2% during the 4th quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after buying an additional 59 shares in the last quarter. Sandy Cove Advisors LLC grew its holdings in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock valued at $605,000 after purchasing an additional 60 shares during the last quarter. LCM Capital Management Inc grew its holdings in shares of Johnson & Johnson by 0.7% during the 4th quarter. LCM Capital Management Inc now owns 9,437 shares of the company’s stock valued at $1,667,000 after purchasing an additional 61 shares during the last quarter. Arbor Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 2.3% during the 4th quarter. Arbor Investment Advisors LLC now owns 2,697 shares of the company’s stock valued at $476,000 after purchasing an additional 61 shares during the last quarter. Finally, Mason & Associates Inc grew its holdings in shares of Johnson & Johnson by 4.9% during the 3rd quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after purchasing an additional 62 shares during the last quarter. Institutional investors own 67.94% of the company’s stock.
Wall Street Analysts Forecast Growth
JNJ has been the topic of several recent research reports. Guggenheim started coverage on shares of Johnson & Johnson in a report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 target price on the stock. Raymond James cut their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 19th. SVB Leerink cut their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Finally, StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, March 16th. They issued a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $173.00.
Johnson & Johnson Trading Down 0.1 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion during the quarter, compared to analyst estimates of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. Johnson & Johnson’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the firm posted $2.67 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be issued a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.91%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s payout ratio is presently 94.56%.
Insider Activity at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Insiders Drive Volatility For Keurig Dr Pepper
- After a 40% Drop, Analysts Remain Bullish on Impinj
- Visa Charges Higher After Better-Than-Expected Q2 Report
- onsemi Puts A Bottom in Chip Stocks, Heads For New Highs
- Can Teladoc Stock Be Resuscitated?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
